Study of Chitosan for Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients

Prostate Cancer Clinical Trial

Official title:

Phase 1b/2 Study of Chitosan for Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03712371
• Other study ID #: 102928
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: January 16, 2019
• Est. completion date: September 7, 2021

Study information

• Verified date: December 2021
• Source: Medical University of South Carolina
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will examine the utility of chitosan for reduction of blood or tissue levels of AGEs in patients with prostate cancer who are clinically stable on androgen-deprivation therapy.

Description:

The overall goal of this study is to identify a safe dose of the metabolic supplement, Chitosan that can help reduce AGE (advanced glycation endproducts) levels in patients with prostate cancer. Chitosan is a naturally occurring substance found in shellfish. This study will be using Chitosan prepared from the shells of cold-water shrimp. Chitosan is approved by the FDA for use in wound dressings and has been used in published clinical trials for weight loss but is not approved for the purposes of this study. AGEs are a type of metabolite, or substance, found in food and produced in the body. The researchers helping conduct this study have found a potential link between AGE levels and cancer. Participation in this study will require three study visits over the course of about 3 months. During these visits subjects will be asked to provide blood and stool samples as well as complete surveys about their quality of life.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 12
• Est. completion date: September 7, 2021
• Est. primary completion date: July 2, 2020
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion:

1. Confirmation of adenocarcinoma of the prostate that is documented by one of the following: pathology report or clinic note with documented history of prostate cancer.

2. Subjects must be receiving ADT with a GnRH agonist or antagonist, with or without an anti-androgen or testosterone synthesis inhibitor. The current testosterone level must be documented to be <50ng/dL at enrollment. Subjects whose ADT is interrupted may enroll or continue on study as long as the testosterone is documented to remain <50ng/dL for the entire duration of study participation. Subjects who have undergone orchiectomy are also eligible.

3. Subjects must have adequate hematologic, renal, and hepatic function at baseline, as follows:

• Hematology parameters: ANC >1000/mcL, platelets > 100,000/mcL, Hgb >8.0gm/dL

• Renal Function: eGFR of = 45mls/min using Cockgroft and Gault formula

• Liver Function: Total bilirubin =ULN, AST and ALT <1.5x ULN

4. Able to swallow and retain oral medication

5. ECOG performance status of 0 - 2

6. Ability to sign written informed consent

7. Testosterone level <50ng/dL at time of enrollment.

8. Age 18 or older.

9. May have had prior radiation therapy, surgery, or cryoablation for primary prostate cancer

10. May have had prior cytotoxic chemotherapy for metastatic prostate cancer, prior treatment with genomically-targeted agents, or Provenge

Exclusion:

1. Known allergy to chitosan or shellfish.

2. History of receiving more than 2 classes of ADT.

3. Chronic constipation (BM < 3x weekly), history of malabsorption or history of daily laxative use.

4. Patients requiring medication administration with lunch or dinner or at a frequency of three or more times per day are not eligible.

5. Current use of chitosan, sevelamer, and/or glucosamine.

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• Chitosan
The starting dose for Chitosan is 500mg twice a day, the second dose level is 1000mg twice a day, the third dose level is 1500mg twice a day, and the fourth dose level is 2000mg twice a day. Each dose level lasts for 28 days.

Locations

Country	Name	City	State
United States	Medical University of South Carolina	Charleston	South Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Medical University of South Carolina

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum tolerated dose (MTD) of Chitosan in PCa subjects.		112 days
Secondary	Change in redox status (RedoxSys, serum oxidized glutathione)		112 days
Secondary	Change in inflammation (plasma cytokines, Toll-like receptor signaling)		112 days
Secondary	Change in insulin resistance (HOMA-IR)		112 days
Secondary	Changes in bowel permeability (plasma endotoxin)		112 days
Secondary	Changes in microbiome diversity (16s rDNA sequencing)		112 days
Secondary	Correlate changes in serum AGE levels (pan-AGE, carboxymethyllysine, methylglyoxal		112 days
Secondary	Measure the frequency of a > 30% reduction in total AGE levels from the pretreatment level.		112 days